Please provide your email address to receive an email when new articles are posted on . SAN ANTONIO — Imlunestrant alone or as part of combination therapy extended PFS for certain patients with ...

Please provide your email address to receive an email when new articles are posted on . Results from a phase 2 study showed that abemaciclib in combination with letrozole shrunk or stabilized tumors ...

Abemaciclib (from Lilly) is heading to become the third of a new class of drugs for use in breast cancer — the cyclin-dependent kinase (CDK) 4/6 inhibitors. The US Food and Drug Administration (FDA) ...

The MONARCH-3 trial is a phase 3, randomized, double-blinded, placebo-controlled trial that evaluated the use of abemaciclib alone and in combination with a non-steroidal aromatase inhibitor (eg, ...

An unrecognizable person holding a medicine box. Adding abemaciclib to adjuvant endocrine therapy can provide long-term benefits for patients with high-risk, HR+, HER2- early breast cancer, updated ...

Women with hormone receptor (HR)–positive, human epidermal growth factor receptor 2 (HER2)–negative breast cancer who have one positive sentinel node and no high-risk features can likely be spared ...

INDIANAPOLIS, Sept. 27, 2021 /PRNewswire/ -- New data from Eli Lilly and Company's (NYSE: LLY) monarchE study for an investigational use of Verzenio® (abemaciclib), in combination with endocrine ...

More than 70% of women with metastatic breast cancer have hormone-receptor positive disease. Resistance to endocrine therapies in this population is common and problematic. Minimizing resistance to ...

INDIANAPOLIS, Oct. 13, 2021 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has approved Eli Lilly and Company's (NYSE: LLY) Verzenio® (abemaciclib), in combination with endocrine therapy ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...